09/2023
Meet us at the 23rd Annual Biotech in Europe Forum, 20th - 21st of September…
09/2023
VCC-001 has the potential to elicitate a humoral and cell-mediated immune response. Antigen presentation takes…
08/2023
Vaccentis performs in silico antigen mapping in collaboration with bioinformatic specialists with extensive background in Oncology…
08/2023
The heterogeneity of tumour-associated antigen and neoantigen expression in solid tumours is a key feature…
07/2023
Vaccentis continues the partnership with the Medical University of Vienna (Gerd Silberhumer and Nina Pilat) to further…
07/2023
Vaccentis is planning to enter a collaboration with the Institute Krems Bioanalytics to optimize CMC aspects of…
06/2023
In the LEADERSNET interview, Martin Munte, CEO of Vaccentis, talks about innovations of his biopharmaceutical…
06/2023
On June 19th Vaccentis held a scientific advisory board with leading clinical experts in urology, oncology,…
06/2023
On June 14th Vaccentis AG held its Annual General Meeting tomorrow and reported on the 2022…
05/2023
Vaccentis attends LSX conference in London and presents the core business strategy for the oncological…
03/2023
Vaccentis attends the Sachs conference and Bio Europe Spring in Basel to present the core…
02/2023
The preclinical studies in cooperation with the University Hospital Vienna are continued in 2023. A…
01/2023
In January 2023, Dr. Ingrid Rauter was appointed Head of R&D and CMO and thus…
12/2022
In December 2022, a Family & Friends funding round was successfully completed to secure continued…
11/2022
The preclinical studies in cooperation with the University Hospital Vienna were consistently continued in 2022…
